Details of the Drug

General Information of Drug (ID: DMOTQ1I)

Drug Name

Ondansetron

Synonyms

DESMETHYLONDANSETRON; Zofran; Zophren; Zudan; Sandoz ondansetron; ZOFRAN IN PLASTIC CONTAINER; Zofran ODT; GR 38032; GR 38032X; GR38032F; Apo-ondansetron; GR-38032F; Novo-ondansetron; Ondansetron (Zofran); PHL-ondansetron; PMS-ondansetron; Ratio-ondansetron; SN-307; Zofran (TN); Zofran ODT (TN); Ondansetron [USAN:INN:BAN]; Ondansetron (JAN/USP/INN); Ondansetron, (+,-)-Isomer; (RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one; 1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one; 9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one; 9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one; 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one

Indication

Disease Entry	ICD 11	Status	REF
Chemotherapy-induced nausea	MD90	Approved	[1]
Malignant glioma	2A00.0	Approved	[2]
Nausea	MD90	Approved	[2]
Vomiting	MD90	Approved	[2]
Alcohol dependence	6C40.2	Phase 2	[1]
Gastroenteritis	N.A.	Investigative	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Antiemetics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

293.4

Logarithm of the Partition Coefficient (xlogp)

2.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 1887 mcgh/L [3]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 572 mcg/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2-4 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Bioavailability: The bioavailability of drug is 9.3% [3]
Clearance: The clearance of drug is 0.38 L/h/kg []
Elimination: 5% of drug is excreted from urine in the unchanged form [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 3 - 4 hours (8 mg oral dose or intravenous dose) []
Metabolism: The drug is metabolized via the hepatic []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.16868 micromolar/kg/day [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.27% [6]
Vd: The volume of distribution (Vd) of drug is 160 L [7]
Water Solubility: The ability of drug to dissolve in water is measured as 5.7 mg/mL [4]

Chemical Identifiers

Formula: C18H19N3O
IUPAC Name: 9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
Canonical SMILES: CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C
InChI: InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3
InChIKey: FELGMEQIXOGIFQ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4595
ChEBI ID: CHEBI:7773
CAS Number: 99614-02-5
DrugBank ID: DB00904
TTD ID: D0K7WK
VARIDT ID: DR00909
INTEDE ID: DR1200
ACDINA ID: D00490

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 3 receptor (5HT3R)	TTNXLKE	NOUNIPROTAC	Agonist	[8]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[10]
Cytochrome P450 2E1 (CYP2E1)	DEVDYN7	CP2E1_HUMAN	Substrate	[11]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[12]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[13]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[14]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[15]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[15]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[16]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Ondansetron

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Promethazine	DM6I5GR	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Promethazine.	Nausea/vomiting [MD90]	[17]
-----------

Coadministration of a Drug Treating the Disease Different from Ondansetron (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Ondansetron and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[17]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Ivosidenib.	Acute myeloid leukaemia [2A60]	[18]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Midostaurin.	Acute myeloid leukaemia [2A60]	[17]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Idarubicin.	Acute myeloid leukaemia [2A60]	[17]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Arn-509.	Acute myeloid leukaemia [2A60]	[19]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Gilteritinib.	Acute myeloid leukaemia [2A60]	[20]
Oliceridine	DM6MDCF	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Oliceridine.	Acute pain [MG31]	[17]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Ondansetron and Rivastigmine.	Alzheimer disease [8A20]	[17]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Ondansetron and Metronidazole.	Amoebiasis [1A36]	[21]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Ondansetron and Ivabradine.	Angina pectoris [BA40]	[19]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Bepridil.	Angina pectoris [BA40]	[17]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Dronedarone.	Angina pectoris [BA40]	[17]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[22]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Cilostazol.	Arterial occlusive disease [BD40]	[17]
Posaconazole	DMUL5EW	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Posaconazole.	Aspergillosis [1F20]	[17]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Levalbuterol.	Asthma [CA23]	[23]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Ondansetron and Pirbuterol.	Asthma [CA23]	[24]
Salbutamol	DMN9CWF	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Salbutamol.	Asthma [CA23]	[23]
Formoterol	DMSOURV	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Formoterol.	Asthma [CA23]	[24]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[19]
Desipramine	DMT2FDC	Major	Additive serotonergic effects by the combination of Ondansetron and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[17]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Clarithromycin	DM4M1SG	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[17]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Ondansetron and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[17]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[25]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[17]
Telithromycin	DMZ4P3A	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Telithromycin.	Bacterial infection [1A00-1C4Z]	[17]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Retigabine.	Behcet disease [4A62]	[17]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Eribulin.	Breast cancer [2C60-2C6Y]	[17]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Lapatinib.	Breast cancer [2C60-2C6Y]	[17]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Bosutinib.	Breast cancer [2C60-2C6Y]	[19]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[26]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[24]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Ondansetron and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[23]
Salmeterol	DMIEU69	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[24]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Ondansetron and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[24]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Ondansetron and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[24]
Dihydrocodeine	DMB0FWL	Moderate	Additive serotonergic effects by the combination of Ondansetron and Dihydrocodeine.	Chronic pain [MG30]	[27]
Levomilnacipran	DMV26S8	Major	Additive serotonergic effects by the combination of Ondansetron and Levomilnacipran.	Chronic pain [MG30]	[17]
Isoproterenol	DMK7MEY	Moderate	Increased risk of ventricular arrhythmias by the combination of Ondansetron and Isoproterenol.	Conduction disorder [BC63]	[23]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Halothane.	Corneal disease [9A76-9A78]	[17]
Sevoflurane	DMC9O43	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Sevoflurane.	Corneal disease [9A76-9A78]	[17]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Probucol.	Coronary atherosclerosis [BA80]	[17]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Pasireotide.	Cushing syndrome [5A70]	[17]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Osilodrostat.	Cushing syndrome [5A70]	[19]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Ondansetron caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[28]
Sertraline	DM0FB1J	Major	Additive serotonergic effects by the combination of Ondansetron and Sertraline.	Depression [6A70-6A7Z]	[17]
Vilazodone	DM4LECQ	Major	Additive serotonergic effects by the combination of Ondansetron and Vilazodone.	Depression [6A70-6A7Z]	[17]
Nefazodone	DM4ZS8M	Major	Additive serotonergic effects by the combination of Ondansetron and Nefazodone.	Depression [6A70-6A7Z]	[17]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Ondansetron and Vortioxetine.	Depression [6A70-6A7Z]	[17]
Isocarboxazid	DMAF1NB	Major	Additive serotonergic effects by the combination of Ondansetron and Isocarboxazid.	Depression [6A70-6A7Z]	[17]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of Ondansetron and Milnacipran.	Depression [6A70-6A7Z]	[17]
Escitalopram	DMFK9HG	Major	Additive serotonergic effects by the combination of Ondansetron and Escitalopram.	Depression [6A70-6A7Z]	[17]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Ondansetron and Desvenlafaxine.	Depression [6A70-6A7Z]	[17]
Clomipramine	DMINRKW	Major	Additive serotonergic effects by the combination of Ondansetron and Clomipramine.	Depression [6A70-6A7Z]	[17]
Doxepin	DMPI98T	Major	Additive serotonergic effects by the combination of Ondansetron and Doxepin.	Depression [6A70-6A7Z]	[17]
Maprotiline	DMPWB7T	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Maprotiline.	Depression [6A70-6A7Z]	[17]
5-hydroxy-L-tryptophan	DMDWZGJ	Major	Additive serotonergic effects by the combination of Ondansetron and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[21]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[17]
Deutetrabenazine	DMUPFLI	Moderate	Additive CNS depression effects by the combination of Ondansetron and Deutetrabenazine.	Dystonic disorder [8A02]	[29]
Ingrezza	DMVPLNC	Moderate	Additive CNS depression effects by the combination of Ondansetron and Ingrezza.	Dystonic disorder [8A02]	[30]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Ondansetron caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[31]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Ondansetron caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[21]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Ondansetron caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[19]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Solifenacin.	Functional bladder disorder [GC50]	[17]
Ketoconazole	DMPZI3Q	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Ketoconazole.	Fungal infection [1F29-1F2F]	[17]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[17]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Ondansetron caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[32]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Ondansetron caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[32]
Procarbazine	DMIK367	Major	Additive serotonergic effects by the combination of Ondansetron and Procarbazine.	Hodgkin lymphoma [2B30]	[17]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[33]
Lopinavir	DMITQS0	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[17]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[17]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Ondansetron caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[34]
Teriflunomide	DMQ2FKJ	Moderate	Increased metabolism of Ondansetron caused by Teriflunomide mediated induction of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[21]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Ondansetron and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[19]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Ondansetron and Phenolphthalein.	Irritable bowel syndrome [DD91]	[17]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Ondansetron caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[19]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Crizotinib.	Lung cancer [2C25]	[35]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Ondansetron caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[36]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Ceritinib.	Lung cancer [2C25]	[17]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Osimertinib.	Lung cancer [2C25]	[37]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Selpercatinib.	Lung cancer [2C25]	[19]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Lumefantrine.	Malaria [1F40-1F45]	[21]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Halofantrine.	Malaria [1F40-1F45]	[38]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Hydroxychloroquine.	Malaria [1F40-1F45]	[39]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Primaquine.	Malaria [1F40-1F45]	[17]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[19]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Ondansetron caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[40]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Ondansetron caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[41]
Arsenic trioxide	DM61TA4	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[42]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Vemurafenib.	Melanoma [2C30]	[17]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and LGX818.	Melanoma [2C30]	[43]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Ondansetron caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[19]
Almogran	DM7I64Z	Major	Additive serotonergic effects by the combination of Ondansetron and Almogran.	Migraine [8A80]	[17]
Frovatriptan	DM7RE8P	Major	Additive serotonergic effects by the combination of Ondansetron and Frovatriptan.	Migraine [8A80]	[17]
Rizatriptan	DMDJMA3	Major	Additive serotonergic effects by the combination of Ondansetron and Rizatriptan.	Migraine [8A80]	[17]
Naratriptan	DMO50U2	Major	Additive serotonergic effects by the combination of Ondansetron and Naratriptan.	Migraine [8A80]	[17]
Lasmiditan	DMXLVDT	Major	Additive serotonergic effects by the combination of Ondansetron and Lasmiditan.	Migraine [8A80]	[17]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Ondansetron caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[44]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Panobinostat.	Multiple myeloma [2A83]	[45]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Ondansetron and Thalidomide.	Multiple myeloma [2A83]	[21]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Ondansetron and Siponimod.	Multiple sclerosis [8A40]	[21]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Ondansetron and Fingolimod.	Multiple sclerosis [8A40]	[17]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Ondansetron and Ozanimod.	Multiple sclerosis [8A40]	[46]
Romidepsin	DMT5GNL	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Romidepsin.	Mycosis fungoides [2B01]	[17]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Nilotinib.	Myeloproliferative neoplasm [2A20]	[17]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Dasatinib.	Myeloproliferative neoplasm [2A20]	[47]
Bupropion	DM5PCS7	Major	Additive serotonergic effects by the combination of Ondansetron and Bupropion.	Nicotine use disorder [6C4A]	[17]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Entrectinib.	Non-small cell lung cancer [2C25]	[21]
Sibutramine	DMFJTDI	Major	Additive serotonergic effects by the combination of Ondansetron and Sibutramine.	Obesity [5B80-5B81]	[17]
Dexfenfluramine	DMJ7YDS	Major	Additive serotonergic effects by the combination of Ondansetron and Dexfenfluramine.	Obesity [5B80-5B81]	[17]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Levomethadyl Acetate.	Opioid use disorder [6C43]	[19]
Lofexidine	DM1WXA6	Moderate	Additive hypotensive effects by the combination of Ondansetron and Lofexidine.	Opioid use disorder [6C43]	[17]
Olaparib	DM8QB1D	Moderate	Increased metabolism of Ondansetron caused by Olaparib mediated induction of CYP450 enzyme.	Ovarian cancer [2C73]	[21]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Rucaparib.	Ovarian cancer [2C73]	[17]
Oxymorphone	DM65AGJ	Moderate	Additive serotonergic effects by the combination of Ondansetron and Oxymorphone.	Pain [MG30-MG3Z]	[27]
Dezocine	DMJDB0Y	Moderate	Additive serotonergic effects by the combination of Ondansetron and Dezocine.	Pain [MG30-MG3Z]	[27]
Buprenorphine	DMPRI8G	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Buprenorphine.	Pain [MG30-MG3Z]	[17]
Hydrocodone	DMQ2JO5	Moderate	Additive serotonergic effects by the combination of Ondansetron and Hydrocodone.	Pain [MG30-MG3Z]	[27]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Triclabendazole.	Parasitic worm infestation [1F90]	[17]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Pimavanserin.	Parkinsonism [8A00]	[48]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Ondansetron caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[49]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Famotidine.	Peptic ulcer [DA61]	[21]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[50]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Lefamulin.	Pneumonia [CA40]	[51]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Ondansetron caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[52]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Degarelix.	Prostate cancer [2C82]	[19]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and ABIRATERONE.	Prostate cancer [2C82]	[19]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Enzalutamide.	Prostate cancer [2C82]	[19]
Relugolix	DMK7IWL	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Relugolix.	Prostate cancer [2C82]	[19]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Bicalutamide.	Prostate cancer [2C82]	[19]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Levomepromazine.	Psychotic disorder [6A20-6A25]	[17]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[53]
Quetiapine	DM1N62C	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Quetiapine.	Schizophrenia [6A20]	[17]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Mesoridazine.	Schizophrenia [6A20]	[17]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Aripiprazole.	Schizophrenia [6A20]	[21]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Iloperidone.	Schizophrenia [6A20]	[17]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Paliperidone.	Schizophrenia [6A20]	[17]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Amisulpride.	Schizophrenia [6A20]	[54]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Asenapine.	Schizophrenia [6A20]	[17]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Pimozide.	Schizophrenia [6A20]	[19]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Ondansetron caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[19]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Ondansetron caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[21]
Armodafinil	DMGB035	Minor	Increased metabolism of Ondansetron caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[55]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Ondansetron and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[17]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[17]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[19]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[17]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Ondansetron caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[19]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[17]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Ondansetron caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[56]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Lenvatinib.	Thyroid cancer [2D10]	[17]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Cabozantinib.	Thyroid cancer [2D10]	[19]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Papaverine.	Tonus and reflex abnormality [MB47]	[57]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[58]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Procainamide.	Ventricular tachyarrhythmia [BC71]	[17]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Propafenone.	Ventricular tachyarrhythmia [BC71]	[17]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Ondansetron and Flecainide.	Ventricular tachyarrhythmia [BC71]	[17]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Ondansetron and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[17]
-----------


⏷ Show the Full List of 163 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Aspartame	E00402	134601	Flavoring agent
FD&C blue no. 2	E00446	2723854	Colorant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Propylparaben sodium	E00567	23679044	Antimicrobial preservative
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium methylparaben	E00543	23663626	Antimicrobial preservative
Sodium stearyl fumarate	E00545	23665634	lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium stearate	E00244	15324	lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hexahydric alcohol	E00083	5780	Diluent; Flavoring agent; Humectant; Plasticizing agent
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
Pregelatinized starch	E00674	Not Available	Binding agent; Diluent; Disintegrant
--------------------


⏷ Show the Full List of 30 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Ondansetron 4 mg tablet	4 mg	Disintegrating Oral Tablet	Oral
Ondansetron 8 mg tablet	8 mg	Disintegrating Oral Tablet	Oral
Ondansetron Hydrochloride eq 8mg base tablet	eq 8mg base	Tablet	Oral
Ondansetron Hydrochloride eq 4mg base tablet	eq 4mg base	Tablet	Oral
Ondansetron 4 mg tablet	4 mg	Oral Tablet	Oral
Ondansetron 8 mg tablet	8 mg	Oral Tablet	Oral
Ondansetron 24 mg tablet	24 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2290).
2	Ondansetron FDA Label
3	Health Canada Approved Drug Products: Sunvepra (asunaprevir) capsule
4	BDDCS applied to over 900 drugs
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Roila F, Del Favero A: Ondansetron clinical pharmacokinetics. Clin Pharmacokinet. 1995 Aug;29(2):95-109. doi: 10.2165/00003088-199529020-00004.
8	Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol. 1998 Oct;10(10):865-70.
9	Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004 Jan;75(1):13-33.
10	The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron. Clin Pharmacol Ther. 1999 Apr;65(4):377-81.
11	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron. Comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos. 1996 May;24(5):602-9.
12	Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med Sci Monit. 2005 Oct;11(10):RA322-8.
13	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
14	Effects of serotonin-3 receptor antagonists on cytochrome P450 activities in human liver microsomes. Biol Pharm Bull. 2006 Sep;29(9):1931-5.
15	Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos. 1995 Nov;23(11):1225-30.
16	Serotonin type-3 receptor antagonists selectively kill melanoma cells through classical apoptosis, microtubule depolymerisation, ERK activation, and NF-B downregulation. Cell Biol Toxicol. 2023 Jun;39(3):1119-1135. doi: 10.1007/s10565-021-09667-0. Epub 2021 Oct 15.
17	Canadian Pharmacists Association.
18	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
19	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
20	Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
21	Cerner Multum, Inc. "Australian Product Information.".
22	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
23	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
24	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
25	Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
26	Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
27	Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
28	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
29	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
30	Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
31	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
32	Villikka K, Kivisto KT, Neuvonen PJ "The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron." Clin Pharmacol Ther 65 (1999): 377-81. [PMID: 10223773]
33	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
34	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
35	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
36	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
37	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
38	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
39	Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
40	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
41	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
42	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
43	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
44	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
45	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
46	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
47	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
48	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
49	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
50	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
51	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
52	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
53	Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
54	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
55	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
56	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
57	Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
58	Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]